Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2Bob W. van Oosten, C. Polman, Frederik Barkhof et al.|Neurology|1996Cited by 733
Accumulation of hypointense lesions ("black holes") on T <sub>1</sub> spin-echo MRI correlates with disease progression in multiple sclerosisL. Truyen, Frederik Barkhof, M.A.A. van Walderveen et al.|Neurology|1996Cited by 465
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trialBob W. van Oosten, Chris H. Polman, Mitchell K.P. Lai et al.|Neurology|1997Cited by 268
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosisAnette H.H. van Boxel-Dezaire, Lex Nagelkerken, Sabine Hoff et al.|Annals of Neurology|1999Cited by 267
PML in a Patient Treated with Dimethyl Fumarate from a Compounding PharmacyBob W. van Oosten, Mike P. Wattjes, Joep Killestein et al.|New England Journal of Medicine|2013Cited by 184